albuterol Side Effects
Also known as: Ventolin, ProAir, Proventil
Analysis of 113,967 adverse event reports submitted to the FDA from 1995 to 2025.
Total Reports
113,967
Death-Related
9,607
8.4% of reports
Hospitalizations
41,765
36.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 9,607 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 3,210 |
| DYSPNOEA | 1,236 |
| PNEUMONIA | 1,136 |
| NAUSEA | 765 |
| OFF LABEL USE | 709 |
| VOMITING | 694 |
| ASTHMA | 672 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 668 |
| RESPIRATORY FAILURE | 663 |
| PYREXIA | 633 |
| CONDITION AGGRAVATED | 626 |
| FATIGUE | 620 |
| SEPSIS | 594 |
| ASTHENIA | 572 |
| PAIN | 539 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 536 |
| DIARRHOEA | 535 |
| ABDOMINAL PAIN | 507 |
| RENAL FAILURE | 491 |
| HEADACHE | 483 |
Reactions in Hospitalization Reports
Top reactions in 41,765 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 7,406 |
| PNEUMONIA | 5,318 |
| ASTHMA | 4,282 |
| NAUSEA | 3,045 |
| COUGH | 2,939 |
| PAIN | 2,834 |
| WHEEZING | 2,729 |
| FATIGUE | 2,581 |
| VOMITING | 2,489 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2,423 |
| DIARRHOEA | 2,414 |
| DRUG INEFFECTIVE | 2,351 |
| FALL | 2,336 |
| PYREXIA | 2,242 |
| HEADACHE | 2,239 |
| ANXIETY | 2,165 |
| ASTHENIA | 2,125 |
| OFF LABEL USE | 2,082 |
| CONDITION AGGRAVATED | 1,954 |
| CHEST PAIN | 1,948 |
Nearby — Related Medications
What the FAERS Data Reveals About albuterol Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 113,967 voluntary reports linked to albuterol and its brand equivalents (Ventolin, ProAir, Proventil), spanning 1995 through 2025. Of those, 9,607 (8.4%) listed death as an outcome and 41,765 (36.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 64% were female and 36% male; age distribution skews toward 45-64, with 26,153 reports in that bracket. The single most reported reaction is dyspnoea with 15,965 submissions, followed by asthma and drug ineffective.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.